Brokerage Firm Rating Update on Biogen (BIIB)

Biogen (BIIB) has an average broker rating of 1.83, which is interpreted as a Buy, as rated by 15 equity analysts. Nonetheless, 8 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. 1 other analysts advise a Buy. Nevertheless, the majority of 6 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.

Biogen (BIIB) : The highest level Biogen (BIIB) is projected to reach is $414 for the short term and the lowest estimate is at $283. The consolidated price target from 14 rating analysts who initiate coverage on the stock is $351.14 and the possibility the share price can swing is $40.66.


For the current week, the company shares have a recommendation consensus of Buy. Also, Morgan Stanley maintains its view on Biogen (NASDAQ:BIIB) according to the research report released by the firm to its investors. The shares have now been rated Overweight by the stock experts at the ratings house. Morgan Stanley lowers the price target from $385 per share to $368 per share on Biogen . The rating by the firm was issued on August 17, 2016.

Biogen (NASDAQ:BIIB): The stock opened at $309.96 and touched an intraday high of $313.72 on Wednesday. During the day, the stock corrected to an intraday low of $309.96, however, the bulls stepped in and pushed the price higher to close in the green at $312.3 with a gain of 0.52% for the day. The total traded volume for the day was 1,155,574. The stock had closed at $310.67 in the previous trading session.

Biogen Inc., formerly Biogen Idec Inc., is a global biopharmaceutical company. The Company is focused on discovering, developing, manufacturing and delivering therapies for neurological, autoimmune and hematologic disorders. The Company develops, manufactures and markets products designed for the treatment of multiple sclerosis (MS) and hemophilia A and B. The Companys marketed products include AVONEX, PLEGRIDY, TECFIDERA, TYSABRI, FAMPYRA for multiple sclerosis (MS), ALPROLIX for hemophilia B, and ELOCTATE for hemophilia A, among others. It also collaborates on the development and commercialization of RITUXAN (rituximab), which is a monoclonal antibody for the treatment of non-Hodgkins lymphoma, chronic lymphocytic leukemia and other conditions and share profits and losses for GAZYVA, which is for the treatment of chronic lymphocytic leukemia.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *